M3 AI Stock Analysis
Want to see JP:2413 full AI Analyst Report?
M3 (2413) AI Stock Analysis
M3
(TSE/TYO:2413)
The score is driven primarily by strong financial performance—re-accelerating growth, solid margins, conservative leverage, and strong free cash flow—partly offset by margin compression and inconsistent operating cash flow conversion. Technicals are mixed with near-term softness despite a positive longer-term trend, and valuation is relatively rich given the mid-20s P/E and modest yield.
M3 (2413) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.90B
- Dividend Yield
- 1.19%
- Average Volume (3M)
- 3.78M
- Price to Earnings (P/E)
- 26.4
- Beta (1Y)
- 0.59
- Revenue Growth
- 9.48%
- EPS Growth
- 2.08%
- Country
- Japan
- Employees
- 17,010
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
M3 Business Overview & Revenue Model
Company Description
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidenc...
How the Company Makes Money
M3 makes money primarily by monetizing its healthcare professional network and digital platforms. Key revenue streams include: (1) marketing and promotional services sold to pharmaceutical and other healthcare-industry companies, such as digital adve...
M3 Financial Statement Overview
Summary
Strong overall fundamentals supported by re-accelerating revenue growth (14.5% in 2026), healthy profitability (~50% gross margin and ~14% net margin), and robust free cash flow generation. Key offsets are margin compression versus prior peaks and uneven operating cash flow conversion.
Income Statement
78PositiveBalance Sheet
86Very PositiveCash Flow
80Positive| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 343.77B | 284.90B | 351.36B | 238.88B | 230.82B | 208.16B |
| Gross Profit | 173.32B | 154.36B | 175.84B | 140.53B | 135.19B | 123.27B |
| EBITDA | 94.21B | 77.71B | 94.52B | 78.11B | 81.82B | 102.51B |
| Net Income | 49.59B | 40.48B | 49.10B | 45.27B | 49.03B | 63.84B |
Balance Sheet | ||||||
| Total Assets | 644.35B | 581.74B | 637.40B | 490.78B | 400.64B | 345.98B |
| Cash, Cash Equivalents and Short-Term Investments | 144.31B | 166.75B | 156.18B | 179.74B | 146.25B | 141.12B |
| Total Debt | 43.09B | 51.42B | 33.15B | 31.78B | 10.38B | 8.30B |
| Total Liabilities | 190.16B | 168.94B | 190.75B | 124.08B | 91.13B | 82.03B |
| Stockholders Equity | 416.77B | 378.44B | 408.22B | 351.92B | 302.63B | 257.84B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 45.45B | 62.58B | 52.90B | 51.20B | 50.40B |
| Operating Cash Flow | 0 | 51.74B | 70.26B | 58.31B | 57.11B | 52.11B |
| Investing Cash Flow | 0 | -39.15B | -15.89B | -29.31B | -27.52B | -26.82B |
| Financing Cash Flow | 0 | -27.16B | -35.47B | -712.00M | -17.25B | -12.96B |
M3 Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2413, the sentiment is Positive. The current price of 1843.00 is below the 20-day moving average (MA) of 1877.98, above the 50-day MA of 1817.67, and above the 200-day MA of 1705.21, indicating a neutral trend. The MACD of 8.19 indicates Positive momentum. The RSI at 49.19 is Neutral, neither overbought nor oversold. The STOCH value of 68.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2413.
M3 Peers Comparison
Overall Rating
- JP:241372Outperform
JP:934165Neutral
JP:448063Neutral
JP:448361Neutral
JP:443854Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:2413 | 72Outperform | JPY 1.28T | 26.36 | 11.33% | 1.19% | 9.48% | 2.08% |
| JP:9341 | 65Neutral | JPY 10.36B | 15.96 | ― | 5.20% | 36.94% | -31.50% |
| JP:4480 | 63Neutral | JPY 80.31B | 42.33 | 12.35% | ― | 24.03% | 34.50% |
| JP:4483 | 61Neutral | JPY 260.81B | 34.63 | ― | 0.45% | 20.50% | 19.27% |
| JP:4438 | 54Neutral | JPY 2.38B | -4.42 | ― | ― | 14.84% | 30.67% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2413 | M3 | 1843.00 | -750.90 | -28.95% | |
| JP:4480 | Medley, Inc. | 2595.00 | 339.00 | 15.03% | |
| JP:4438 | Welby Inc. | 274.00 | -146.00 | -34.76% | |
| JP:4483 | JMDC Inc. | 3975.00 | -403.70 | -9.22% | |
| JP:9341 | GENOVA Inc. | 577.00 | 36.36 | 6.72% |
M3 Corporate Events
M3 Advances Share Buyback Program with ¥1.5 Billion September Repurchases
M3, Inc. has repurchased 859,800 of its own common shares on the Tokyo Stock Exchange between September 1 and September 30, 2026, at a total cost of about ¥1.5 billion. The buyback is being executed under a board-approved program authorizing up to 20...
M3 Reports Progress on Ongoing Share Repurchase Program
M3, Inc. has disclosed the latest status of its ongoing share repurchase program authorized by its board in May 2026. Between August 1 and August 31, the company bought back 1,116,200 common shares on the Tokyo Stock Exchange for a total of about 2.0...
M3 Sets Final Terms for New Stock Option Issuance
M3, Inc. has finalized key terms for a new issuance of stock options in the form of share acquisition rights, following an earlier board decision made on August 6, 2026. The company set the total number of share acquisition rights at 1,028 units, est...
M3 Issues Cautionary Presentation on Strategic Outlook
M3, Inc. has released a presentation that outlines its forecasts, plans, and management targets, emphasizing that these projections are based on current data and may differ from actual future results. The company also notes that some external informa...
M3 Introduces New Stock Option Plan to Align Employees with Long-Term Shareholder Value
M3, Inc. has approved the issuance of new stock options in the form of share acquisition rights, aimed at boosting employee motivation and aligning management with shareholder interests over the medium to long term. The options will be granted to 277...
M3 posts modest sales growth but weaker profits, keeps full-year outlook
M3, Inc. reported consolidated revenue of ¥90.1 billion for the three months ended June 30, 2026, a 4.5% year-on-year increase, while operating profit declined 8.6% and profit attributable to owners of the parent fell 23.4%, reflecting margin pressur...
M3 Reports No Share Buybacks to Date Under Approved ¥20 Billion Program
M3, Inc. reported that during the period from July 1 to July 31, 2026, it did not repurchase any of its own common shares under the share buyback program authorized by its board on May 1, 2026. The board’s resolution permits buybacks of up to 20 mill...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026